Eli Lilly may be on the brink of reshaping the pharma landscape, with its treatments, Mounjaro (tirzepatide) for obesity and the highly anticipated donanemab for early symptomatic Alzheimer’s disease.
During DCAT this year, CEO Gaston Salinas from Botanical Solution Inc., (BSI), sat down with Liza Laws, the senior editor of OSP and BPR to discuss his company’s pioneering work in revolutionizing vaccine adjuvant production.
Cytiva has announced the launch of its Xcellerex magnetic mixer – a single-use mixing system designed to address challenges faced by customers engaged in large-scale mAb, vaccine and genomic medicine manufacturing processes.
Pfizer’s drug Velsipity (etrasimod), for the treatment of moderate to severe ulcerative colitis (UC), recently received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).
In the fast-paced domain of pharmaceutical contract development and manufacturing organizations (CDMOs), Selkirk Pharma believes it stands out as a beacon of innovation and reliability.
Specific doses of Eli Lilly’s GLP-1 blockbuster drugs Mounjaro and Zepbound are currently facing a supply shortage, and frustrated patients are urging the pharma giant to act – fast.
Bio Pharma Reporter and Outsourcing Pharma is back with our latest instalment of movers and shakers - breaking down all the key pharma industry appointments that you should know about. KBI Biopharma, Veranova and Kindeva Drug Delivery are among the companies...
Patrick Thiaville is chief scientific officer of Exothera Nucleic Acids, a viral vector CDMO (contract manufacturing and development organization) using standard and innovative bioproduction platforms to rapidly deliver affordable viral vector-based vaccines...
Elisa Cascade is the chief product officer at Advarra and is responsible for driving the clinical research company's technology product vision and management. We had a fascinating and inspiring conversation with her - touching on imposter syndrome,...
Great Ormond Street Hospital (GOSH) has announced its new plan to ‘revolutionise’ how children living with rare diseases can gain access to cutting-edge gene therapy.
Pfizer has been accused of ‘bringing discredit’ on the pharma industry after senior employees promoted its ‘unlicensed’ COVID-19 vaccine through social media at the height of the pandemic.
Recurring urinary tract infections (UTIs) can be prevented for up to nine years with a simple oral spray vaccine, a ‘breakthrough’ British trial has shown.
In an exclusive interview with Dr Vanessa Zann, (pictured below) executive drug development consultant at Quotient Sciences, OSP delved into the forefront of pharmaceutical research and development.
Last week (April 5), the American Association for Cancer Research (AACR) welcomed the industry to the San Diego Convention Center for the AACR Annual Meeting 2024.
Pharma giant Novo Nordisk is firing back after Senator Bernie Sanders took a stand against the ‘outrageous’ prices of its wildly popular drugs, Ozempic and Wegovy.
Today, just two in ten patients have access to CAR-T therapy in the US. Considering this challenging landscape, the shift has focused from academic centers to community clinics, as they may be able to serve more patients.
Molecure S.A., a leading biotechnology company focused on drug discovery and development, has unveiled its annual report for 2023 at the start of the new financial year.
Cartherics has entered a collaborative research agreement with TiCARos, to assess the company's proprietary CLIP-CAR technology in its induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells.
Dr Laura Trotta joined CluePoints in 2015 and moved into her current role as vice president of research in January 2022, where she leads a team of research scientists responsible for developing new statistical and machine learning algorithms to assess...
Ipsen is expanding its oncology pipeline by securing the global licensing rights to an antibody-drug conjugate (ADC) for solid tumors from Sutro Biopharma, its first drug in the category.
Consumer health company Haleon has published a first-of-its kind study highlighting the significant positive impact that its nasal decongestant Otrivin can have on patients’ quality of life.
The FDA has agreed to permanently remove several social media posts urging people not to take ivermectin for the treatment of COVID-19, after a lawsuit brought by three doctors accused the regulatory body of interfering with their ability to practice...
AstraZeneca CEO Sir Pascal Soriot has been awarded one of the highest honours by science institution SCI for his role in ‘accelerating scientific innovation’ and for leading the company’s global COVID-19 vaccination programme.
From math hater to a leader in clinical data, it’s been a long journey for Jennifer Visser-Rogers, vice president for statistical research and consultancy at Phastar.
“When you have people who like what they do and believe they’re having an impact, you can do anything – more than any project or investment. Prioritise your teams and people because they’re your biggest asset.”
Curve Therapeutics, a biotech pioneering an intracellular screening platform addressing complex and challenging disease targets, has announced the publication of an article in the Journal of the American Chemical Society (JACS).
This week, the pharma industry will descend on Pennsylvania Convention Center for Reuters Pharma USA, North America’s largest cross-functional pharma gathering.
The recent submission of clinical trial data for Sanofi/Regeneron’s Dupixent and Verona’s Ensifentrine to the U.S. FDA indicates the entry of new therapies for chronic obstructive pulmonary disease (COPD) in 2024.
Dr. Claudia Zylberberg is a scientist and founder, board member and former CEO of Akron Biotech, a company that makes materials and technologies to support advanced therapy development. We spoke to her about her career, personal triumphs and candidacy...
AstraZeneca recently announced its £650 million investment in the UK, held up by Chancellor Jeremy Hunt as a ‘vote of confidence’ in the country’s life sciences sector.
Since Roche's Zelboraf (vemurafenib)gained FDA approval in 2011, significant strides have been made in BRAF-targeted cancer therapies, underscoring the significance of combating BRAF mutations in melanoma.
With the pharma and healthcare landscape increasingly being shaped by artificial intelligence (AI), the US Food and Drug Administration (FDA) has taken proactive steps to outline a comprehensive strategy for regulating AI in medical products.
Within the current treatments of Parkinson’s disease (PD) there is an unmet need for addressing the loss of dopaminergic neurons and non-motor symptoms.
The U.S. Food and Drug Administration has cleared AGC Biologics’ Milan site to begin manufacturing of Orchard Therapeutics’ Lenmeldy (atidarsagene autotemcel), a gene therapy for early-onset metachromatic leukodystrophy (MLD).
Eli Lilly is partnering with ecommerce titan Amazon to deliver its weight loss drug Zepbound straight to patient’s doors, in a bid to address ongoing shortages.
Biopharma company Clene has published ‘impactful’ new research into CNM-Au8, its investigational drug in development for the treatment of neurodegenerative diseases.
ReciBioPharm has partnered with pre-clinical gene therapy company GeneVentiv Therapeutics to advance development of an Adeno-Associated Virus (AAV)-based universal gene therapy for haemophilia, and the first to treat haemophilia patients with inhibitors.
DP World, a global leader in supply chain solutions, has launched over 100 freight forwarding offices worldwide in a bold move aimed at bolstering support for the global healthcare sector.
With a treatment for hypoparathyroidism in late-stage development and other promising drugs in Amolyt's pipeline, the $1.05 billion deal is the latest in big pharma's push into rare disease research
